Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the safety, quality and efficacy of therapeutic goods, including medicines, medical devices, and blood and tissues, in Australia. The Act was introduced to address the need for a comprehensive legal framework to ensure that therapeutic goods available in the Australian market are safe, effective and of high quality. The Therapeutic Goods Administration, under the Department of Health, is the relevant authority responsible for administering the Act. The policy objective of the Act is to protect public health by ensuring that therapeutic goods meet the necessary standards and are not represented as being of a quality that they are not. The Act also seeks to facilitate innovation in the therapeutic goods industry while ensuring that the public has access to safe and effective therapeutic goods. The Act provides for the regulation of the manufacture, importation, supply and advertising of therapeutic goods, as well as the establishment of standards for their quality and safety.

Scope and Application

The Therapeutic Goods Act 1989 applies to a wide range of entities involved in the manufacture, supply, advertising, and sponsorship of therapeutic goods in Australia. This includes companies, individuals, and other entities that produce, supply, or claim therapeutic benefits for goods. The Act regulates the quality, safety, and efficacy of therapeutic goods, such as medicines, medical devices, blood, and tissues, ensuring that they meet the necessary standards before they can be legally marketed or supplied within Australia. The Act has a broad jurisdictional reach, operating under the Commonwealth of Australia, and applies to all states and territories. While the Act applies to a variety of therapeutic goods, certain products are excluded or exempted from its provisions, such as blood and tissues that are for non-commercial use and are not supplied for therapeutic purposes. The application of the Therapeutic Goods Act 1989 may be extended or restricted through subordinate instruments, such as regulations and codes, which provide further detail on specific aspects of the legislation.

Key Provisions

The Therapeutic Goods Act 1989, as published in the Gazette (C2018G00544), details the revocation of licences for the manufacture of therapeutic goods. Under section 41(1)(d) of the Act, the Secretary has revoked the licences of several manufacturers by written notice. The revoked licences include that of PlusLife (Licence No. MI-25052005-LI-000576-2) based in Nedlands, Western Australia; Eurofins ams Laboratories Pty Ltd (Licence No. MI-2013-LI-07582-1) located in Seventeen Mile Rocks, Queensland; The Pharmaceutical Plant Company Pty Ltd (Licence No. MI-10012005-LI-000349-2) in Bayswater North, Victoria; Pfizer Australia Pty Ltd (Licence No. MI-10022005-LI-000433-1) in West Ryde, New South Wales; and Eris Pharmaceuticals (Australia) Pty Ltd (Licence No. MI-2013-LI-03598-1) in South Melbourne, Victoria. The revocations were carried out at the request of the manufacturers themselves. The Therapeutic Goods Act 1989 imposes specific obligations on entities that hold a licence to manufacture therapeutic goods. These entities are required to adhere to stringent manufacturing standards to ensure the safety and quality of the products they produce. The Act mandates that the manufacturing processes and facilities must meet regulatory requirements, and periodic inspections may be conducted to ensure compliance. Manufacturers are also obligated to report any adverse events or quality issues associated with their products to the Therapeutic Goods Administration. Breach of the obligations under the Therapeutic Goods Act 1989 can result in severe consequences. Under section 41(1)(d) of the Act, the Secretary has the authority to revoke a manufacturer's licence if they fail to comply with the regulatory requirements. Additionally, if a manufacturer knowingly distributes unsafe or substandard therapeutic goods, they may face criminal charges. The maximum penalties for such offences can include substantial fines and imprisonment. In civil cases, affected parties may seek compensation for any harm caused by non-compliance with the Act. The seriousness of the repercussions underscores the importance of adhering to the regulatory standards set forth by the Therapeutic Goods Act 1989.